TIDE signature was pressure tested on pre-CPI treatment tumor tissue samples of melanoma patients and in this cohort it performed better in predicting response patterns than PDL-1 levels, TMB, and an IFNγ signature (Jiang et al., 2018). This evidence concerns the gene CD274 and neoplasm.